

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M. 8193 - TEVA / ANDA

SECTION 1.2

Description of the concentration

The concentration involves the proposed acquisition of sole control by Teva Pharmaceutical Industries Ltd. ("**Teva**") of the Anda Distribution business ("**Anda**"), currently held by Allergan plc (the "**Proposed Transaction**"). The Proposed Transaction qualifies as a concentration under Article 3(1)(b) and Article 5(2), second subparagraph, of Council regulation No. 139/2004, following Teva's recent acquisition of Allergan Generics.

The activities of the parties are as follows:

- **Teva:** an Israeli pharmaceutical company active in the development, manufacturing, marketing, sale and distribution of generic and proprietary pharmaceutical products as well as biopharmaceuticals and active pharmaceutical ingredients worldwide.
- **Anda:** a US distributor of generic, brand, specialty and Over-the-Counter pharmaceutical products to retail independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics and physician offices. Its activities and turnover are limited entirely to the US.